Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19

Study of Tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ?crinical trial study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20081027001411N4

Enrollment

Registered

2020-07-09

Start date

2020-04-29

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. COVID-19, virus not identified

Interventions

Intervention 1: Intervention group: Patients hospitalized with COVID-19 disease will receive 8mg/kg Tocilizumab (Roche) in addition to their standard treatment. If the patients condition is not stabl

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: COVID-19 patients confirmed by positive PCR ?test for SARS-CoV-19 or confirmed by abnormal CT scan finding (bilateral, sub pleural, peripheral ground glass ?opacities), With blood oxygen saturation 24 high CRP rate, lymphopenia < 1100 not responding to standard COVID-19 treatment.

Exclusion criteria

Exclusion criteria: A history of malignancies, positive pro-calcitonin and active infection (Including latent or active TB infection) A history of taking immunosuppressive drugs and corticosteroids

Design outcomes

Primary

Measure	Time frame
Radiographic features Findings. Timepoint: Before treatment and 6 weeks after treatment. Method of measurement: CT scan.;Mortality rate. Timepoint: Before and after treatment. Method of measurement: Observation.;Need an oxygen therapy. Timepoint: Before and after (at day 5 after treatment and discharge time). Method of measurement: The need on oxygen therapy (Yes or No), If yes: Type of oxygen therapy (nasal cannula, mask oxygen, reserve mask, noninvasive ?ventilation (NIV), and ?invasive ventilation)?.;O2 saturation. Timepoint: Before and after (at day 5 after treatment and at discharge time). Method of measurement: Pulse Oximeter.	—

Measure

Time frame

Radiographic features Findings. Timepoint: Before treatment and 6 weeks after treatment. Method of measurement: CT scan.;Mortality rate. Timepoint: Before and after treatment. Method of measurement: Observation.;Need an oxygen therapy. Timepoint: Before and after (at day 5 after treatment and discharge time). Method of measurement: The need on oxygen therapy (Yes or No), If yes: Type of oxygen therapy (nasal cannula, mask oxygen, reserve mask, noninvasive ?ventilation (NIV), and ?invasive ventilation)?.;O2 saturation. Timepoint: Before and after (at day 5 after treatment and at discharge time). Method of measurement: Pulse Oximeter.

—

Secondary

Measure	Time frame
Laboratory tests (including CBC, Hb, HCT, FBS, TG, Cho, ESR, CRP, VBG, IL-6, Ferritin, CPK, ALT, AST, Troponin, and D-dimer). Timepoint: Before and after (at day 5 after treatment and discharge time). Method of measurement: Para-clinical.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmadreza Jamshidi

Tehran University of Medical Sciences

jamshida@sina.tums.ac.ir+98 21 8822 0065

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026